CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG-CANCER

  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (11-1) , 941-945
Abstract
Fifty-four patients with non-small cell lung cancer were treated with a combination of cyclophosphamide, doxorubicin and cisplatin (CAP). A 35% response rate was seen, with a median survival of 380 days for the responders, compared to median survival times of 150 days for the nonresponders and 229 days for the group. Twenty-four percent of these patients had received prior treatment. All of the nonresponding patients had died by 438 days; 8 of 19 responders lived > 425 days. The survival curve for the nonresponders was similar to that for a historical control group not given chemotherapy. This drug regimen evidently has some efficacy in the treatment of non-small cell lung cancer.

This publication has 0 references indexed in Scilit: